Bank of Montreal Can Acquires New Shares in Prestige Consumer Healthcare Inc. (NYSE:PBH)

Bank of Montreal Can purchased a new position in shares of Prestige Consumer Healthcare Inc. (NYSE:PBH) in the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund purchased 6,209 shares of the company’s stock, valued at approximately $372,000.

A number of other institutional investors also recently added to or reduced their stakes in the business. BlackRock Inc. boosted its position in Prestige Consumer Healthcare by 12.4% during the 1st quarter. BlackRock Inc. now owns 9,115,718 shares of the company’s stock worth $482,584,000 after acquiring an additional 1,004,337 shares during the period. Vanguard Group Inc. lifted its holdings in shares of Prestige Consumer Healthcare by 0.6% in the third quarter. Vanguard Group Inc. now owns 5,647,622 shares of the company’s stock valued at $281,421,000 after buying an additional 32,646 shares during the period. Dimensional Fund Advisors LP lifted its holdings in shares of Prestige Consumer Healthcare by 0.4% in the first quarter. Dimensional Fund Advisors LP now owns 3,448,246 shares of the company’s stock valued at $182,552,000 after buying an additional 12,790 shares during the period. Macquarie Group Ltd. lifted its holdings in shares of Prestige Consumer Healthcare by 39.6% in the first quarter. Macquarie Group Ltd. now owns 2,753,431 shares of the company’s stock valued at $172,447,000 after buying an additional 781,431 shares during the period. Finally, State Street Corp lifted its holdings in shares of Prestige Consumer Healthcare by 1.2% in the third quarter. State Street Corp now owns 1,944,342 shares of the company’s stock valued at $96,887,000 after buying an additional 22,886 shares during the period. Institutional investors and hedge funds own 99.95% of the company’s stock.

Wall Street Analyst Weigh In

Several brokerages have recently weighed in on PBH. TheStreet lowered Prestige Consumer Healthcare from a “b” rating to a “c+” rating in a report on Thursday, September 7th. StockNews.com lowered Prestige Consumer Healthcare from a “buy” rating to a “hold” rating in a research report on Monday, November 6th. Royal Bank of Canada cut their target price on Prestige Consumer Healthcare from $110.00 to $103.00 and set a “sector perform” rating on the stock in a research report on Wednesday, November 15th. Finally, BMO Capital Markets cut their target price on Prestige Consumer Healthcare from $124.00 to $117.00 and set an “outperform” rating on the stock in a research report on Wednesday, November 15th. Two research analysts have rated the stock with a hold rating and two have given a buy rating to the stock. According to data from MarketBeat.com, Prestige Consumer Healthcare presently has a consensus rating of “Moderate Buy” and a consensus price target of $97.00.

Insider Activity at Prestige Consumer Healthcare

In related news, SVP Mary Beth Fritz sold 2,540 shares of the company’s stock in a transaction on Thursday, September 14th. The stock was sold at an average price of $58.92, for a total transaction of $149,656.80. Following the transaction, the senior vice president now directly owns 15,934 shares of the company’s stock, valued at $938,831.28. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. 1.60% of the stock is owned by insiders.

Prestige Consumer Healthcare Stock Down 1.1 %

NYSE:PBH opened at $58.31 on Monday. The firm has a market capitalization of $2.89 billion, a price-to-earnings ratio of -35.13, a PEG ratio of 1.71 and a beta of 0.57. Prestige Consumer Healthcare Inc. has a 1-year low of $55.96 and a 1-year high of $68.54. The company has a current ratio of 2.99, a quick ratio of 1.75 and a debt-to-equity ratio of 0.82. The business’s fifty day moving average price is $58.82 and its 200 day moving average price is $59.48.

About Prestige Consumer Healthcare

Prestige Consumer Healthcare Inc, together with its subsidiaries, develops, manufactures, markets, distributes, and sells over-the-counter (OTC) health and personal care products in the United States and internationally. The company operates in two segments, North American OTC Healthcare and International OTC Healthcare.